Roy Baynes, Merck Research Laboratories CMO (file photo)
#ASCO21: With Bristol Myers set for its own big LAG-3 update at ASCO, Merck touts early success for a potential competitor
Bristol Myers Squibb is set to be the belle of the ball at this year’s ASCO with a big late-stage readout for its anti-LAG-3 antibody …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
